Stock market today: S&P 500 climbs as health care, tech gain; Nvidia earnings loom
Investing.com -- Bio-Rad Laboratories, Inc. (NYSE:BIO) shares surged 12.7% after the life science research and clinical diagnostics company reported second quarter earnings that substantially exceeded analyst expectations, driven by stronger-than-anticipated revenue and improved operating margin guidance.
The company reported adjusted earnings per share of $2.61 for the second quarter, significantly outpacing the analyst estimate of $1.73. Revenue came in at $651.6 million, beating the consensus estimate of $615.2 million and representing a 2.1% increase compared to $638.5 million in the same quarter last year. On a currency-neutral basis, quarterly sales increased 1.0% YoY.
"In a highly dynamic environment, we delivered solid quarterly results, both in terms of revenue and operating margin, through focused execution and careful expense management," said Norman Schwartz, Bio-Rad’s Chairman and Chief Executive Officer.
The Life Science segment led growth with sales of $262.8 million, up 4.9% compared to the same period in 2024, driven by increased process chromatography and food safety product sales. The Clinical Diagnostics segment reported sales of $388.8 million, essentially flat compared to the prior year.
Bio-Rad also raised its full-year 2025 outlook, now expecting non-GAAP currency-neutral revenue growth of approximately 0 to 1.0%, compared to its previous guidance range of a 1.0% decline to 1.5% growth. The company also increased its non-GAAP operating margin forecast to 12.0-13.0%, up from its prior expectation of 10.0-12.0%.
The company recently completed the acquisition of droplet digital PCR developer Stilla Technologies, expanding its Droplet Digital PCR offering with the launch of its QX Continuum system complemented by the acquired QX700 series of instruments.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.